A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
British journal of cancer（2023）
摘要
EudraCT registration number: 2012-001527-13; Clinicaltrials.gov registration number: NCT01792310.
更多查看译文
关键词
Cancer therapy,Phase I trials,Biomedicine,general,Cancer Research,Epidemiology,Molecular Medicine,Oncology,Drug Resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要